frontier-banner
Frontiers
Home>Frontiers>

Molecular Cancer | IGF2BP3 Promotes Esophageal Squamous Cell Carcinoma Progression and M2 Macrophage Polarization via USP36-Mediated β-Catenin Stabilization

Molecular Cancer | IGF2BP3 Promotes Esophageal Squamous Cell Carcinoma Progression and M2 Macrophage Polarization via USP36-Mediated β-Catenin Stabilization
--

This study reveals a novel mechanism by which IGF2BP3 regulates the tumor immune microenvironment, providing a critical target validation strategy for combined immunotherapy approaches in esophageal squamous cell carcinoma.

 

Literature Overview

The article titled "IGF2BP3 promotes M2 macrophage polarization and ESCC progression by increasing USP36-mediated β-catenin stabilization," published in Molecular Cancer, systematically explores the specific pathways through which the RNA-binding protein IGF2BP3 reshapes the tumor immune microenvironment in esophageal squamous cell carcinoma (ESCC) via non-canonical post-transcriptional regulatory mechanisms.

Background Knowledge

Esophageal squamous cell carcinoma is a highly malignant tumor with a poor prognosis and suboptimal response to conventional radiotherapy, chemotherapy, and immunotherapy. The core bottleneck lies in the severe immunosuppressive state within the tumor microenvironment, particularly the massive infiltration of M2 macrophages. Current research on the Wnt/β-catenin signaling pathway has largely focused on gene mutations or protein phosphorylation modifications, while the mechanism by which RNA-binding proteins influence β-catenin stability through post-transcriptional regulation to drive immune escape remains unclear. This study identifies IGF2BP3 as a key post-transcriptional regulator that specifically binds to USP36 mRNA to promote its translation. This subsequently stabilizes β-catenin through deubiquitination, ultimately inducing TGF-β secretion and driving M2 macrophage polarization, thereby filling a gap in the understanding of RNA-binding proteins in the regulation of the ESCC immune microenvironment.

 

 

Research Methods and Experiments

The authors integrated single-cell RNA sequencing data with clinical samples, utilizing a 4NQO-induced mouse esophageal cancer model and immunocompetent and immunodeficient mouse xenograft models. Combined with flow cytometry, multiplex immunofluorescence, and histochemical staining, they deeply analyzed the in vivo function of IGF2BP3. Key evidence showed that knocking down IGF2BP3 significantly inhibited tumor growth and M2 macrophage infiltration, with this effect being more pronounced in immunocompetent mice, confirming its immunoregulatory function.

At the molecular mechanism level, the study employed RNA immunoprecipitation, polysome profiling, ubiquitination assays, and molecular docking techniques. Experiments confirmed that IGF2BP3 does not affect USP36 mRNA stability but instead binds to the CDS region of USP36 mRNA via its KH3-4 domains to enhance its translation efficiency. Overexpression of USP36 could reverse the β-catenin degradation caused by IGF2BP3 knockdown, while β-catenin activation further upregulated the transcription and secretion of TGF-β.

Furthermore, virtual screening identified the cardiac glycoside drug digoxin as a direct binder and inhibitor of IGF2BP3. Its potential to block the IGF2BP3/USP36/β-catenin axis and enhance the efficacy of PD-1 blockade therapy and paclitaxel was validated in organoid models and in vivo in mice.

Key Conclusions and Perspectives

  • IGF2BP3 is specifically highly expressed in esophageal squamous cell carcinoma and is upregulated with tumor progression; its high expression correlates positively with poor patient prognosis and M2 macrophage infiltration, suggesting its value as a prognostic marker.
  • IGF2BP3 mediates the deubiquitination of β-catenin by USP36 by promoting USP36 translation rather than affecting its mRNA stability. This is the key mechanism for stabilizing β-catenin protein and activating the Wnt signaling pathway.
  • The activated β-catenin signaling pathway directly drives the transcription and secretion of TGF-β, thereby inducing the polarization of tumor-associated macrophages toward the immunosuppressive M2 phenotype and constructing an immunosuppressive microenvironment.
  • As a direct inhibitor of IGF2BP3, digoxin can effectively disrupt the aforementioned signaling axis, significantly inhibiting tumor growth and synergistically enhancing the anti-tumor efficacy of PD-1 antibodies and chemotherapy drugs.

Research Significance and Prospects

This discovery provides a novel target strategy for drug development in esophageal squamous cell carcinoma, namely reversing the immunosuppressive microenvironment by targeting IGF2BP3 or its downstream effector molecules. For clinical monitoring, IGF2BP3 and M2 macrophage markers can serve as potential indicators for assessing patient immune status and prognosis. In terms of disease modeling, this study suggests that when constructing esophageal cancer immune microenvironment models, special attention should be paid to the regulatory role of RNA-binding proteins on the Wnt pathway and immune cell polarization, which will help more precisely screen combination therapy regimens.

 

 

Conclusion

This study thoroughly analyzes the core role of IGF2BP3 in the occurrence, development, and immune escape of esophageal squamous cell carcinoma, revealing a novel mechanism by which it drives M2 macrophage polarization via the USP36-β-catenin-TGF-β axis. This finding not only expands the understanding of the function of RNA-binding proteins in the tumor immune microenvironment but also provides a highly potential intervention strategy for clinical translation. Specifically, utilizing the approved drug digoxin to target IGF2BP3 offers an economically viable and feasible new solution to overcome immunotherapy resistance in esophageal squamous cell carcinoma. From laboratory mechanism elucidation to the exploration of clinical combination therapies, this research lays a solid foundation for improving the survival prognosis of patients with esophageal squamous cell carcinoma and building a more comprehensive diagnosis and treatment system.

 

Reference:
Zhongxian Tian, Yongjia Zhou, Yunpeng Zhao, Honglei Wu, and Xiaogang Zhao. IGF2BP3 promotes M2 macrophage polarization and ESCC progression by increasing USP36-mediated β-catenin stabilization. Molecular Cancer.
Chai-1 is a multimodal molecular structure prediction foundation model, focusing on accurate 3D structure prediction of biomolecules. It achieves state-of-the-art performance in drug discovery and biomolecular interaction studies. Its core value lies in using deep learning techniques to decode the folded structures and interaction mechanisms of biomolecules, providing critical support for targeted drug design and protein function studies.